Journal: Bioactive Materials

Article Title: A catalytically active and recyclable bioelastomer inspired by metalloenzymes

doi: 10.1016/j.bioactmat.2026.02.053

Figure Lengend Snippet: Cytocompatibility of Cu-PIAS. ( A ) Viability, as measured by ATP content, of human umbilical vein endothelial cells cultured with media containing extracts of 15-Cu-PIAS, Latex (Positive), or PCL (Negative) over three days. ( B ) Representative images of cell morphology after 24 h exposure to material extract-containing media, visualized by Calcein AM (Green) staining. Additional staining with ethidium homodimer-1 (red) indicates the presence of non-viable cells.

Article Snippet: Briefly, endothelial growth medium supplemented with 5% fetal bovine serum, growth factors, ascorbic acid, and hydrocortisone (Promocell C-22121) was incubated at 37 °C for 72 h under agitation alone, or in the presence of 15-Cu-PIAS (6 cm 2 /mL), PCL (6 cm 2 /mL), or latex (3 cm 2 /mL) sheets cut into several 6 mm × 6 mm squares.

Techniques: Cell Culture, Staining

Journal: Bioactive Materials

Article Title: Mesenchymal stromal cells-loaded 3D radially aligned composite scaffold with potentiated paracrine signaling for sequential bone regeneration

doi: 10.1016/j.bioactmat.2026.02.059

Figure Lengend Snippet: Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, VEGF, HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.

Article Snippet: ELISA kits for PGE2 (Cat. No. E-EL-0034), TGF-β (Cat. No. E-EL-0162), VEGF (Cat. No. E-EL-R2603), and HGF (Cat. No. E-EL-R0496) were purchased from Elabscience (Wuhan, China).

Techniques: Confocal Microscopy, Fluorescence, Staining, Cell Culture, Expressing

Journal: iScience

Article Title: DPPA inhibits melanoma by targeting angiogenesis through activating autocrine IFN-γ-CXCL9/10/11-CXCR3 axis in vascular endothelial cells

doi: 10.1016/j.isci.2026.116309

Figure Lengend Snippet: DPPA suppresses angiogenesis through the activation of the IFN-γ-CXCL9/10/11-CXCR3 axis in vascular endothelial cells (A) Angiogenesis PCR array for human dermal microvascular endothelial cells (HDMECs) treated with DMSO and DPPA at a concentration of 10 μM for 48 h. The relative expression levels were calculated as the log2 fold change, and the differentially expressed genes were selected on the basis of a log2 ≤ −2 or ≥2. (B) KEGG classification of differentially expressed genes in A. HDMECs were treated with DMSO and DPPA (10 μM) for 48 h, and RNAs and proteins were collected to analyze the expression of the IFN-γ-CXCL9/10/11 axis at both the transcriptional and protein levels using RT-qPCR (C) and western blotting (D) assays. n = 3 technical replicates from 3 biological replicates for each group. (E) 3D models of docking poses for DPPA and receptors (including IFN-γ, CXCL9, CXCL10, and CXCL11) predicted by Autodock Vina Tools. (F) 2D model of the interaction between DPPA and IFN-γ. HDMECs were treated with IFN-γ for 48 h, after which the RNAs and proteins were collected and subjected to RT-qPCR (G) and western blotting (H) to quantify the expression levels of CXCL9, CXCL10, CXCL11, p65, and pp65. β-actin was served as an internal control. (G) n = 3 technical replicates from 3 biological replicates for each group. (H) n = 3 biological replicates for each group. (I) HDMECs were treated with NF-κB inhibitor (NF-κB-IN-11) for 48 h, and RNAs were collected to analyze the expression of the IFN-γ at the transcriptional levels using qRT-PCR. β-actin was served as an internal control. n = 3 biological replicates for each group. Cell migration (J) and tube formation on Matrigel (K) of HDMECs treated with DMSO, DPPA, or DPPA with CXCL9/10/11-CXCR3 axis-blocking neutralizing antibodies. n = 3 technical replicates from 3 biological replicates for each group. Scale bars: 100 μm. Data are presented as mean ± SD. Significant effects: p values were calculated using Student’s t test (two-tailed unpaired t test) for C, D, G, H, and I, and one-way ANOVA for J and K. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 and ns: p > 0.05 (compared with the control/DMSO group).

Article Snippet: Human dermal microvascular endothelial cells (HDMECs, Procell system, Wuhan, China) were maintained in endothelial cell growth medium supplemented with growth supplements (EGM, CC-3124, Lonza), and have been authenticated by Procell system using CD31 immunofluorescence (IF) staining and been tested for mycoplasma contamination.

Techniques: Activation Assay, Concentration Assay, Expressing, Quantitative RT-PCR, Western Blot, Control, Migration, Blocking Assay, Two Tailed Test